Skip to content
Screener

Harrow HROW Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

AbbVie logo
AbbVieABBV
$44M+4.8%
Bausch + Lomb logo
Bausch + LombBLCO
$68M0.0%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$977M+3.6%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$63K+150%

Other financials

Income statement

See full
Revenue$70.7M+10.9%
Gross profit$50.4M+6.0%
Operating income-$11.0M-196%
Net income-$17.3M-446%
EPS (diluted)-$0.46-454%

Balance sheet

See full
Cash & equivalents$83.9M+58.4%
Total debt$308.4M-32.0%
Total equity$15.2M-69.4%
Total assets$416.8M+20.8%

Cash flow

See full
Operating cash flow-$9.8M
CapEx$491.0K+196%
Free cash flow-$10.2M

Valuation

See full
Market cap$1.51B+22.5%
Enterprise value$1.73B+6.3%
P/S5.5×+0.1×

Profitability

See full
Gross margin73.3%-1.3pp
Operating margin-1%-7.3pp
Net margin-19.8%+18.0pp
FCF margin1.8%+1.3pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity20.3×+11.2×
Current ratio2.2×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The source filing: Harrow’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055271
Line itemJune 30,2026December 31,2025
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 37,484,233 and 37,229,159 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively37,00037,000
Additional paid-in capital216,559,000208,933,000
Accumulated deficit(201,396,000)(156,524,000)
TOTAL HARROW, INC. STOCKHOLDERS’ EQUITY15,200,00052,446,000
Noncontrolling interests(355,000)(355,000)
TOTAL STOCKHOLDERS’ EQUITY14,845,00052,091,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$416,816,000$399,482,000

Item 1. Financial Statements

FAQ

What is Harrow's noncontrolling interests in subsidiaries?
Harrow (HROW) reported noncontrolling interests in subsidiaries of -$355K in Q2 2026.
How has Harrow's noncontrolling interests in subsidiaries changed year-over-year?
Harrow's noncontrolling interests in subsidiaries decreased by 0.0% year-over-year, from -$355K to -$355K.
What is the long-term trend for Harrow's noncontrolling interests in subsidiaries?
Over 5 years (2020 to 2025), Harrow's noncontrolling interests in subsidiaries has grown at a 0.0% compound annual growth rate (CAGR), from -$355K to -$355K.
What does noncontrolling interests in subsidiaries mean?
This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.

Ask your AI about Harrow's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude